Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis.

医学 荟萃分析 食管癌 倾向得分匹配 食管切除术 随机化 新辅助治疗 内科学 随机对照试验 置信区间 放化疗 癌症 外科 乳腺癌
作者
Berend J. van der Wilk,Ben M. Eyck,Wayne L Hofstetter,Jaffer A. Ajani,Guillaume Piessen,Carlo Castoro,Rita Alfieri,Jong H. Kim,Sung‐Bae Kim,Heidi Furlong,T. N. Walsh,Daan Nieboer,Bas P. L. Wijnhoven,Sjoerd M. Lagarde,J Jan B van Lanschot
出处
期刊:PubMed [National Institutes of Health]
卷期号:275 (3): 467-476 被引量:39
标识
DOI:10.1097/sla.0000000000004930
摘要

OBJECTIVE: To compare overall survival of patients with a cCR undergoing active surveillance versus standard esophagectomy. SUMMARY OF BACKGROUND DATA: One-third of patients with esophageal cancer have a pathologically complete response in the resection specimen after neoadjuvant chemoradiotherapy. Active surveillance may be of benefit in patients with cCR, determined with diagnostics during response evaluations after chemoradiotherapy. METHODS: A systematic review and meta-analysis was performed comparing overall survival between patients with cCR after chemoradiotherapy undergoing active surveillance versus standard esophagectomy. Authors were contacted to supply individual patient data. Overall and progression-free survival were compared using random effects meta-analysis of randomized or propensity score matched data. Locoregional recurrence rate was assessed. The study-protocol was registered (PROSPERO: CRD42020167070). RESULTS: Seven studies were identified comprising 788 patients, of which after randomization or propensity score matching yielded 196 active surveillance and 257 standard esophagectomy patients. All authors provided individual patient data. The risk of all-cause mortality for active surveillance was 1.08 [95% confidence interval (CI): 0.62-1.87, P = 0.75] after intention-to-treat analysis and 0.93 (95% CI: 0.56-1.54, P = 0.75) after per-protocol analysis. The risk of progression or all-cause mortality for active surveillance was 1.14 (95% CI: 0.83-1.58, P = 0.36). Five-year locoregional recurrence rate during active surveillance was 40% (95% CI: 26%-59%). 95% of active surveillance patients undergoing postponed esophagectomy for locoregional recurrence had radical resection. CONCLUSIONS: Overall survival was comparable in patients with cCR after chemoradiotherapy undergoing active surveillance or standard esophagectomy. Diagnostic follow-up is mandatory in active surveillance and postponed esophagectomy should be offered to operable patients in case of locoregional recurrence.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
衣锦夜行发布了新的文献求助10
1秒前
zyf完成签到,获得积分10
1秒前
泠然冷云完成签到 ,获得积分10
2秒前
2秒前
2秒前
Hou完成签到,获得积分10
2秒前
nancyshine完成签到,获得积分10
2秒前
xhyqaq完成签到,获得积分10
4秒前
万能图书馆应助malistm采纳,获得10
4秒前
情怀应助happy采纳,获得10
5秒前
川上富江完成签到 ,获得积分10
5秒前
crescent完成签到 ,获得积分10
6秒前
good1luck2完成签到,获得积分10
7秒前
akaia完成签到 ,获得积分10
8秒前
淡竹发布了新的文献求助10
8秒前
美丽谷槐发布了新的文献求助10
10秒前
xilon完成签到,获得积分10
11秒前
Elias完成签到 ,获得积分10
11秒前
李满际完成签到 ,获得积分10
15秒前
哎呀完成签到 ,获得积分10
15秒前
Tardigrade完成签到,获得积分10
17秒前
Zero完成签到,获得积分10
17秒前
超级采白完成签到,获得积分10
18秒前
kankan完成签到 ,获得积分10
21秒前
21秒前
21秒前
xrkxrk完成签到 ,获得积分0
23秒前
在水一方应助衣锦夜行采纳,获得10
25秒前
0323完成签到 ,获得积分10
26秒前
malistm发布了新的文献求助10
26秒前
祝你发财完成签到,获得积分10
27秒前
小周完成签到,获得积分10
27秒前
旷盐完成签到,获得积分10
28秒前
科研通AI6.4应助落寞涑采纳,获得10
28秒前
FFFF完成签到,获得积分10
29秒前
QAQSS完成签到 ,获得积分10
29秒前
晏小敏完成签到,获得积分10
30秒前
111完成签到 ,获得积分10
30秒前
你不要过来啊完成签到,获得积分10
30秒前
燕子笺完成签到,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Nondestructive Testing Handbook: Vol. 4, Thermal and Infrared Testing (IR), 4th ed 800
作者名:Kristopher P. Plain,悉尼大学的,目前只能查到其四篇论文,想找到其博士论文 590
Évora na Idade Média 555
Soil mites of the family Rhagidiidae (Actinedida: Eupodoidea). Morphology, Systematics, Ecology 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Radical Reactions 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7363858
求助须知:如何正确求助?哪些是违规求助? 8972924
关于积分的说明 19072539
捐赠科研通 7008798
什么是DOI,文献DOI怎么找? 3223773
关于科研通互助平台的介绍 2387479
邀请新用户注册赠送积分活动 2204605